Lightlake, NIDA collaborate to develop opioid addiction treatment

 A treatment for opioid addiction has been co-developed by Lightlake Therapeutics and the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA), which is part of Drugs of Abuse Pipeline Products Market.

Within 18 months, the collaboration aims to develop a clinical development plan and regulatory pathway that will lead to FDA approval and the commercialization of a new pharmaceutical treatment for opioid addiction's complications.



Dr. Roger Crystal, chief executive officer of Lightlake, stated: This is a growing health concern in the United States and a difficult problem to solve because multiple opioid-based drugs are used illegally and prescribed.

"A pharmaceutical solution that is efficient, practical, and cost-effective is being developed by Lightlake by utilizing its substantial expertise in opioid antagonists."

To know about the assumptions considered for the study, Download for Free Sample Report

The agreement stipulates that DPMCDA will sponsor a Phase I investigation into the pharmacokinetic properties of Lightlake's product candidate that will include 14 healthy volunteer subjects.

IDA anticipates submitting an IND for a larger final study if the study is successful.

Comments

Popular posts from this blog

Exploring Ecopetrol's Key Locations: A Comprehensive Guide

Understanding the Competitive Landscape of BlackBerry Ltd.

Understanding Aflac's Growth: A Financial Analysis of the Last Quarter